Guanosine triphosphate (trisodium salt hydrate)


CAS No. : 207300-85-4

(Synonyms: GTP (trisodium salt hydrate))

207300-85-4
Price and Availability of CAS No. : 207300-85-4
Size Price Stock
50mg $50 In-stock
100mg $70 In-stock
200mg $120 In-stock
500mg $240 In-stock
1g $420 In-stock
5 g Get quote
10 g Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-12695B
M.Wt: 1000.00
Formula: C10H13N5Na3O14P3·xH2O
Purity: >98 %
Solubility: H2O : ≥ 150 mg/mL
Introduction of 207300-85-4 :

Guanosine triphosphate (GTP) trisodium salt hydrate is a critical nucleotide and regulator of cellular metabolism. Guanosine triphosphate trisodium salt hydrate promotes ribosomal DNA localization, pre-rRNA transcription and ribosome biogenesis by binding to RNA polymerase I and GPN proteins (GPN1/3). Guanosine triphosphate trisodium salt hydrate links MYC-dependent ribosome biogenesis to nucleotide sufficiency, acts as a metabolic gatekeeper supporting protein synthesis, DNA/RNA synthesis and cellular signal transduction, while also participating in the physiological activities of pancreatic β-cells and serving as an oxidative substrate for reactive oxygen species. In small cell lung cancer with high MYC expression, Guanosine triphosphate trisodium salt hydrate accumulates through the IMPDH-driven synthetic pathway, thereby affecting apoptosis and mitotic processes. Guanosine triphosphate trisodium salt hydrate is used in the research of small cell lung cancer, hepatoblastoma and cellular metabolism[1][2][3]. In Vitro:Primary MYC-high human small-cell lung cancer tumors have elevated endogenous guanosine triphosphate levels independent of proliferation status[1].
Guanosine triphosphate (GTP depletion via 1 μM MPA; 12 h) reduced protein synthesis in chemoresistant DMS53-CR human small-cell lung cancer cells, while restoring guanosine triphosphate levels (20 μM guanosine; 12 h) rescued protein synthesis activity[1].
Guanosine triphosphate binding to MYC-upregulated GPN1 and GPN3 GTPases is required for RNA polymerase I localization, ribosome biogenesis, and proliferation in MYC-high H82 human small-cell lung cancer cells, and constitutively GTP-bound GPN1/GPN3 mutants protect cells from guanosine triphosphate depletion-mediated inhibition of these activities[1].
Depletion of cellular GTP (1 μg/ml mycophenolic acid; 1-24 h) in HIT-T15 insulin-secreting β-cells potently inhibits mitogenesis, with significant inhibition observed as early as 1 hour and near-complete inhibition after 6-24 hours of treatment[2].
Depletion of cellular GTP (1.6-6.3 μg/ml mycophenolic acid; 18 h) in HIT-T15 and INS-1 insulin-secreting β-cells inhibits Ca2+-stimulated insulin secretion[2].
Guanosine triphosphate (1 mM; 4 h at 37 °C) undergoes oxidation to oxo8GTP in the presence of a ROS-generating system (1 mM L-ascorbic acid + 10 μM cupric sulfate), with oxo8GTP levels increasing ~4-fold and GTP levels showing a small significant decrease relative to control[3].

Your information is safe with us.